Literature DB >> 25124683

The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial.

Joanna K Soczynska1, Lakshmi N Ravindran2, Rima Styra3, Roger S McIntyre4, Anna Cyriac5, Marena S Manierka6, Sidney H Kennedy7.   

Abstract

Decrements in cognitive function are a common feature of Major Depressive Disorder (MDD), and whether distinct classes of antidepressants differentially affect memory in these individuals has not been sufficiently evaluated. In this study we sought to determine the effect of escitalopram and bupropion XL on memory and psychosocial function. Forty-one individuals (18-50 years) with MDD were enrolled in an 8-week, double-blind, double-dummy, randomized controlled comparative trial of bupropion XL and escitalopram. Thirty-six participants completed pre and post memory assessments. Verbal, non-verbal and working memory were evaluated with a comprehensive neuropsychological battery. Psychosocial function was assessed with the Sheehan Disability Scale and Endicott Work Productivity Scale. Escitalopram and bupropion XL significantly improved immediate as well as delayed verbal and nonverbal memory, global function (all p≤0.001), and work productivity (p=0.045), with no significant between-group differences. Improvement in immediate verbal memory exerted a direct influence on improvement in global function (p=0.006). Treatment with either escitalopram or bupropion XL was associated with improvement in memory and psychosocial function in adults with MDD.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Bupropion XL; Clinical trial; Cognition; Escitalopram; Functional outcomes; Major depressive disorder; Memory

Mesh:

Substances:

Year:  2014        PMID: 25124683     DOI: 10.1016/j.psychres.2014.06.053

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Effects of bupropion sustained release on task-related EEG alpha activity in smokers: Individual differences in drug response.

Authors:  Jian Zhu; Ryan P Coppens; Norka E Rabinovich; David G Gilbert
Journal:  Exp Clin Psychopharmacol       Date:  2017-02       Impact factor: 3.157

Review 2.  The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Vanessa C Evans; Golnoush Alamian; Jane McLeod; Cindy Woo; Lakshmi N Yatham; Raymond W Lam
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 3.  The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Joshua D Rosenblat; Ron Kakar; Roger S McIntyre
Journal:  Int J Neuropsychopharmacol       Date:  2015-07-25       Impact factor: 5.176

4.  Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice.

Authors:  Yan Li; Connie Sanchez; Maria Gulinello
Journal:  Int J Neuropsychopharmacol       Date:  2017-06-01       Impact factor: 5.176

5.  The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.

Authors:  Ioana Florea; Henrik Loft; Natalya Danchenko; Benoît Rive; Melanie Brignone; Elizabeth Merikle; Paula L Jacobsen; David V Sheehan
Journal:  Brain Behav       Date:  2017-02-02       Impact factor: 2.708

6.  Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder.

Authors:  Jeong-Ok Lee; Ju-Wan Kim; Hee-Ju Kang; Jin-Pyo Hong; Jae-Min Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-11-30       Impact factor: 2.582

7.  Comparing the Therapeutic Effects of Crocin, Escitalopram and Co-Administration of Escitalopram and Crocin on Learning and Memory in Rats with Stress-Induced Depression.

Authors:  Mehran Joodaki; Maryam Radahmadi; Hojjatallah Alaei
Journal:  Malays J Med Sci       Date:  2021-08-26

Review 8.  Cognitive remission: a novel objective for the treatment of major depression?

Authors:  Beatrice Bortolato; Kamilla W Miskowiak; Cristiano A Köhler; Michael Maes; Brisa S Fernandes; Michael Berk; André F Carvalho
Journal:  BMC Med       Date:  2016-01-22       Impact factor: 8.775

9.  Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.

Authors:  Michael E Thase; Carl Gommoll; Changzheng Chen; Kenneth Kramer; Angelo Sambunaris
Journal:  Int Clin Psychopharmacol       Date:  2016-11       Impact factor: 1.659

10.  Baseline predictors of cognitive change in the treatment of major depressive episode: systematic review.

Authors:  Zoe A Barczyk; Katie M Douglas; Richard J Porter
Journal:  BJPsych Open       Date:  2020-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.